Author: editor

Partnership to fulfil skilling requirements of 8-10 lakhs aspirants in the next 5 years

 

Avanse Financial Services, India’s new age, technologically advanced education-focused NBFC, partnered with the National Skill Development Corporation (NSDC) to provide easy, fast, and affordable financing solutions for the youth of the country interested in fulfilling their skilling requirements. This collaboration is a progressive step towards catering to the growing need for a skilled workforce in the country across various sectors by assisting the aspirants in acquiring the required skills with the help of customised financing solutions.

Skill-based education or vocational training is extremely crucial as employers expect potential employees to have practical skills and the required expertise along with academic degrees. Technical and Vocational Education & Training (TVET) enables people to acquire the necessary skills, which makes them job-ready and thus, positively impacts the economy in the long-run. This unique partnership will assist Avanse Financial Services in creating an empowered workforce in India with the help of the institutions affiliated with NSDC through a result-oriented framework that corresponds with the need of the industry.

On the commencement of this collaboration, Mr. Amit Gainda, MD & CEO, Avanse Financial Services said, “Skill development is extremely crucial, as it can contribute to structural transformation and economic growth by enhancing employability and labour productivity. India is one of the youngest countries in the world, with more than 62% of the population in the working-age group and more than 54% of the total population below 25 years of age. This creates a large pool of human resources with high-untapped potential for development.”

He further said, “We are delighted to partner with NSDC as it will give us an impeccable opportunity to strengthen our purpose of democratising education and education financing in India. This will enable us to contribute towards developing a ‘skilled India’, a nation with a future-ready young population geared up to reach the zenith of success. We believe this partnership will enable us to amplify our reach and thus, fulfil our mission of making education financing seamless, affordable and accessible for every deserving Indian student.”

Mr. Ved Mani Tiwari, COO and Officiating CEO, NSDC stated, “Access to finance is critical for democratisation of education and skills. Partnerships with NBFCs like Avanse Financial Services help NSDC move one step closer towards its core purpose, ‘Skills4All, Anytime, Anywhere’, as it helps achieve financial inclusion of those sections of our society who otherwise can’t imagine acquiring skills for new age employment/entrepreneurship opportunities in India or overseas.”

Avanse Financial Services has fulfilled the educational dreams of ~2.5 lacs academic aspirants across 3,000+ institutes and 22,000+ courses in ~50 countries. The firm has also provided growth and working capital to ~1K educational institutes catering to over ~5-6 lacs students.

Cyril Amarchand Mangaldas advised the book running lead managers, namely, Kotak Mahindra Capital Company Limited, Morgan Stanley India Company Private Limited, BofA Securities India Limited, and Citigroup Global Markets India Private Limited (“BRLMs”) in relation to the initial public offer of equity shares of Delhivery Limited (“Delhivery”) aggregating to INR 52,350 million (the “Offer”).

Delhivery is the largest and fastest growing fully integrated logistics player in India (in terms of revenue for Fiscal 2021), and provides a full-range of logistics services. Delhivery operates a high-quality logistics infrastructure, working with a vast network of domestic and global partners.

The Capital Markets team of Cyril Amarchand Mangaldas was led by Yash Ashar, Partner & Head – Capital Markets; Gokul Rajan, Partner; with support from Nayan Jain, Principal Associate; Aniran Ghoshal, Senior Associate; along with Jhalak Shah, Associate; and Avinash Gautam, Associate.

The Offer comprised a fresh issue of 82,152,503 equity shares of Delhivery aggregating to INR 40,000 million and an offer for sale of 25,364,585 equity shares of Delhivery aggregating to INR 12,350 million, for cash at a price of INR 487 per equity share. The Offer also included a reservation of 432,900 equity shares aggregating to INR 200 million for eligible employees and a discount of INR 25 per equity share was offered to eligible employees.

Other Parties and Advisers to the transaction included Linklaters Singapore Pte. Ltd. (acted as International legal advisers to the BRLMs); Latham & Watkins LLP (acted as International legal advisers to Delhivery); and Morrison and Foerster LLP (acted as International legal advisers to the SVF Doorbell (Cayman) Ltd).

The equity shares of Delhivery were listed on the stock exchanges on May 24, 2022.

View article…

(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same)

BENGALURU, India, June 15, 2022 /PRNewswire/ — Bengaluru headquartered Fintech platform, Money View, has announced its first ESOP buyback for its employees. With Money View’s profits growing tremendously over the last 18 months, the company has decided to reward the employees with this ESOP buyback. The company has initiated a buyback in June’22 where all the existing employees who have completed one year with Money View will be eligible to participate and sell upto 20% of their vested shares in this buyback. The company also plans another buyback by June 2023 with more to follow. With positive unit economics for the last four years, and company-level profitability growing over the last 1.5 years, Money View has taken various initiatives to reward its employees in the past as well. In October last year, the company had announced an early appraisal for all its employees along with additional cash bonuses. Money View with tremendous growth and product expansion plans, aims to hire 600 employees across Tech, Product & Analytics roles among other areas. Puneet Agarwal, Co-Founder and CEO, said, “We’re amongst very few startups who’re growing profitably. This has only been possible because of the collective conviction and the contribution of the entire team. With this buyback programme, we are celebrating and acknowledging the hard work and passion of our colleagues.” Money View has been growing 4x year-over-year, and is on a trajectory to reach more than $1 billion AUM by the end of the year. About Money View: Founded in 2014, Money View aims to provide access to world class financial products to every Indian with a Smartphone and a Bank Account through a suite of financial products backed by Data and Tech. Money View is a series-D funded company with Tier-1 investors like Tiger Global, Accel Partners, Ribbit Capital, Evolvence India, Winter Capital Partners amongst others. Logo: https://mma.prnewswire.com/media/1762976/Money_View_Logo.jpg (Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same)

Genes2Me Pvt. Ltd., one of the leading IVD solution manufacturer of India, is elated to announce the launch of its CoviEasy Self-Test Rapid Antigen test kit for COVID-19 that is easy to use and give faster results in 10 minutes. Backed by AI driven Mobile App, this IVD product delivers high level of sensitivity and concordance of more than 98% accuracy.

CoviEasy: COVID-19 Rapid Antigen Self Test by Genes2Me

CoviEasy has undergone stringent quality checks at ICMR approved Validation center and further received approval from CDSCO India. CoviEasy test can be easily performed by following simple instructions provided on the Mobile App (which is available on both Android and iOS platforms) leading to Automated Reporting of test results from this Mobile App itself.

The CoviEasy test involves couple of easy and simple steps as is conducted with a nasal swab sampling, wherein the swab first need to be inserted in the nostrils. The swab needs to be dipped in the buffer tube and swirl 8-10 times in the extraction buffer. The Buffer is then dropped onto the CoviEeasy test device which shows test result as either positive or negative. The test device also comes with a unique QR code for unique patient data entry and accurate report generation.

Mr. Neeraj Gupta, the Founder and CEO of Genes2Me Pvt. Ltd. while commenting on the launch of product said, “Now that many of us are opting for “At-home” test kits as our first line of defense against COVID, “Accuracy” becomes non-negotiable/most Important factor. We understood the need of the hour and came up with a test kit which is more than 98% accurate. Our Covieasy kit will provide almost the assurances of RTPCR with the convenience of “at-home” self-test kit. We plan to help the society with India’s most accurate kit and meet the requirement with our advanced manufacturing unit.”

About Genes2Me Pvt. Ltd.

Genes2Me Pvt. Ltd., founded in 2016, is now one of India’s leading companies in the field of IVD Kit manufacturing and molecular diagnostics. Genes2Me has State-of-Art manufacturing facility for IVD kits and has worked tirelessly to provide people with high-quality IVD Kits and Point of care solutions for last so many years. It has provided lot of premium quality IVD solutions for COVID-19 such as Real-time PCR Kits, RNA Extraction Kits, Rapid Tests, Next-Generation Sequencing (NGS) Kits and Multiplexed Genotyping assays. These IVD kits have demonstrated accuracy, sensitivity, and specificity, as well as the ability to deliver faster results.

All Genes2Me products listed above are by Genes2Me Private Limited.

For more information, please visit www.genes2me.com.

View article…

(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same)

• In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19).
• The study is the first evaluation of the efficacy and safety of Reparixin an IL-8 inhibitor in patients with severe COVID-19 pneumonia.
• Results from the Phase 2 trial were presented at the American Thoracic Society (ATS) 2022 International Conference and published in Infectious Diseases and Therapy

MILAN, June 13, 2022 /PRNewswire/ — Dompé farmaceutici S.p.A (“Dompé”) today announced results from its Phase 2 clinical trial demonstrating that, in patients in severe COVID-19 Pneumonia, Reparixin led to an improvement in clinical outcomes when compared with the standard of care, a larger phase 3 clinical study is needed to confirm these results. Results from the Phase 2 trial are published in Infectious Diseases and Therapy and were presented at the scientific sessions of the ATS 2022 International Conference in San Francisco, California.

Acute lung injury and acute respiratory distress syndrome (ARDS) are common complications in patients with COVID-19.¹ As part of its commitment to invest in research for unmet medical needs, Dompé conducted an open-label, multi-center study to evaluate the inhibition of IL-8 which is known to be associated with cytokine release syndrome connected to Covid-19 disease.

“Reparixin is a new investigational molecule that seems to have a novel application in patients with acute respiratory inflammation induced by COVID-19. It was well tolerated in clinical studies,” said Giovanni Landoni, MD, Director of CARE (Center for Intensive Care and Anesthesiology) at Hospital San Raffaele in Milan, Italy. “The outcomes as compared to the standard of care may now be reduced by the widespread use of COVID-19 vaccines, but the obtained results indicated continued investigation would be valuable in patients with acute respiratory inflammation.”

Fifty-five patients were randomized 2:1 to receive 1200 mg of oral Reparixin, an inhibitor of IL-8, three times daily or the standard of care for up to 21 days. The rate of clinical events was statistically significantly lower in the Reparixin group compared to those assigned to the group receiving standard of care (27% vs. 42.1%, p=0.02). Treatment with Reparixin was well-tolerated in terms of treatment-emergent adverse events, laboratory test and vital sign parameters².

“Dompé, along with the rest of the biopharmaceutical world, has worked with urgency to fight COVID-19 and its complications,” said Flavio Mantelli, Chief Medical Officer at Dompé. “While vaccines have helped to mitigate severity of disease, in-hospital treatment options for those who are most seriously impacted remain limited. We are dedicated to this patient population, we are looking forward to continuing our clinical development program to evaluate the potential to reduce COVID-19 respiratory complications.”

About the Study³

The study was an open-label, multicenter, randomized, phase 2 clinical trial designed to assess the efficacy and safety of oral Reparixin in adult patients hospitalized with severe COVID-19 pneumonia from May 5, 2020, until November 27, 2020 and now released for the first time. The study enrolled 55 adults (aged 18–90 years old) hospitalized with severe COVID-19 pneumonia, assigned randomly 2:1 to receive 1200mg Reparixin orally three times daily or standard of care (SOC) for up to 21 days. At least one treatment emergent adverse event occurred in 3 patients in the Reparixin group, and 5 patients in SOC. Reparixin overall appeared to be well tolerated.

All patients received the standard care based on their clinical need, including COVID-19 medications, as per local standard therapy at the trial site hospital and in line with international guidelines.

Please refer to NCT04794803 for additional clinical trial details.

About Dompé

Dompé is a privately-held biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of R&D and medical innovation. Today, Dompé, with Headquarters in Milan, employs more than 800 employees worldwide, with a commercial operations hub in the San Francisco Bay Area, U.S.

Forward Looking Statements

This press release refers to certain information that may not coincide with expected future results. Dompé firmly believes in the soundness and reasonableness of the concepts expressed. However, some of the information is subject to a certain degree of indetermination in relation to its research and development activities and the necessary verifications to be performed by regulatory bodies. Therefore, as of today, Dompé cannot guarantee that the expected results will be consistent with the information provided above.

References

1. Tzotzos SJ, et al. Crit Care. 2020 Aug 21;24(1).

2. A phase 2 multicenter, randomized, controlled study to evaluate the efficacy and safety of Reparixin in hospitalized adult patients with COVID-19 pneumonia, ATS 2022 International Conference in San Francisco, California.

3. https://www.springer.com/journal/40121

Photo – https://mma.prnewswire.com/media/1837356/Dompe_Farmaceutici.jpg

Logo – https://mma.prnewswire.com/media/1837355/Dompe_Farmaceutici_Logo.jpg

(Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same)

Gone are the days when directors would vie for big budget projects, popular starcast, larger than life storyline. These days a socially relevant film that entertains while passing a message to the society is exciting enough. That’s precisely how debutant Director Jai Basantu Singh feels about his maiden venture Janhit Mein Jaari. “I really couldn’t have found a better project to kickstart my directorial journey,” says Singh.

Director Jai Basantu Singh

t wouldn’t be wrong to say that Jai Basantu Singh’s journey to film industry was predestined. His mother was a huge film buff, and he grew up amidst film shoots and film screenings. “My mother was total film buff and would watch all films first day first show. She would take me to watch a lot of films also. That’s where I picked up the love for cinema. I grew up in Goregaon, Mumbai. That’s where most of the film studios are located. I still remember, I would bunk school and go and watch shootings on the sets for hours. I knew even then; this is the industry I wanted to get in. I wanted to be the man, the name called director. While many of my friends would be interested in watching the actors, I used to be fascinated by this person who would call the shots. The one everyone would listen to and follow. I didn’t know what a director was but I knew back then too, this is who I wanted to be. This was my dream in watching the person in my childhood,” says Singh with certainty.

Janhit Mein Jaari didn’t just fall in Singh’s lap. There were long, struggle some years before getting his chance to helm a full length feature film. Singh recalls his journey and says, “When I entered the industry, I went straight into production and it didn’t take much time for me to realise that direction was my true calling. I worked as an assistant director for 3-4 years and then joined Zee TV as campaign and promo director. I shot 600-700 campaigns and promos of fiction and reality shows. That’s where my journey into direction began. My boss then, Puneet Goenka and Ashwini Yardi really gave me a free hand to shoot the way I wanted. I would really owe a great deal of my learning years to Zee Tv and both of them. In 2008 I quit Zee and went onto independently direct campaigns and promos of almost all big broadcasters. In 2009 recession came and that’s when i started directing TV shows as set up director where my journey of telling a story from 30 sec to 30 min began. I owe a great deal of my journey upto this point to television shows. I couldn’t be where I am today if it weren’t for all the campaigns and TV shows I directed.”

Singh directed many popular and successful shows like Ye Un Dino Ki Baat Hai, Ek Duje Ke Vaste, Ye Pyaar Nahi To Kya Hai, Ye Rishta Kya Kehlata Hai, Namune, Jeannie Aur Jiju many hit shows.
I came on this project as Screenplay writer but wherever I used to narrate the script be it to actors, studios, or producers they always acknowledged of how effortlessly I narrate without even looking at the script even once that too for straight two and half hours. That is when my team, producers and studios started telling me that I should direct the film. Seeing the faith people had in me, I got the strength to direct this film.

He further adds, “Janhit Mein Jaari is a challenging subject. It’s about a woman who’s a salesgirl for condoms. In a country that still finds condom as a taboo word, I had to be very mindful to treat this subject delicately. I was walking a thin line. I didn’t want this film to be preachy but pass a good message at the same time. Didn’t want people to make fun of it but wanted to make this film entertaining too. But things eventually fell in place and I got the talented actress Nushrratt Bharuccha to work with who couldn’t be more right for this role. Even the rest of the cast was all very supportive. I really want this film to be a family entertainer and not a tv commercial people awkwardly move away from at homes.”

View article…

(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same)

Micro, Small and Medium Enterprise (MSME)-focused fintech start-up HostBooks today announced that it has raised $3 Million in a Series-A funding round led by Razorpay, one of India’s Leading Full-Stack Financial Services Company. HostBooks plans to utilize the fund to not only add new features to its existing product suite but also to develop innovative products including a deep learning-based Business Intelligence System and an AI-based Posting and Recommendation System. Hostbooks intends to utilize the Series-A funding to further scale its operations and enhance its existing product suite with the launch of new products supporting order management, neo-banking, advanced inventory & production management and AI-based business decision making tools to better support its wide customer base in the country. With this, HostBooks will be a step closer to becoming a one-stop shop for all Business and Finance Operations needs of MSMEs in India. Commenting on the announcement, Kapil Rana, Founder, HostBooks said “We are simplifying and automating the entire business process by focusing on the sources of the transactions, banking, accounting, and tax compliances with an integrated end-to-end business management solution. With the growth in the economy combined with tax norms, the process of accounting and statutory compliance has become more complex. HostBooks, with its large range of services like billing, accounting, inventory management, payroll, compliance management, banking, and advanced business reporting, envisages making the whole process automated, easy to understand, hassle-free, and efficient.” “We share a common vision with Razorpay, which is to build the financial backbone for businesses in India and enable them to thrive. This funding is a major step forward in that direction. Through Razorpay’s support and expertise, we would not only be able to make business processes simpler for entrepreneurs but also give them the tools they need to fast track the growth of their business,” added Biswajit Mishra, Co-founder, HostBooks. HostBooks has transformed tedious backend business processes including accounting and compliance for MSME/SME through a single sign-on collaborative platform. With over 250,000 businesses on its platform, HostBooks has been able to reduce costs of business operations by up to 70%. Along with many features, HostBooks also offers an in-built e-Document Management System with free cloud storage. Commenting on this funding Harshil Mathur, CEO & Co-founder, Razorpay said, “Small businesses are a major driver of the Indian economy and we, at Razorpay have been on a mission to enable them in every step of their growth journey. It is promising to see that companies like HostBooks are playing a critical role in creating a thriving growth environment for small businesses. It gives me immense pleasure for Razorpay to be a part of HostBooks’ growth journey. With our shared vision of fostering growth for businesses with our unified financial management solutions, we would work together towards building a stronger, frictionless business operations SaaS and banking ecosystem for millions of MSMEs in India.” HostBooks was founded by Kapil Rana in 2017 and was joined at an early stage by Biswajit Mishra. HostBooks is an innovative cloud-based financial platform that offers end-to-end solutions that cater to the complete value chain of businesses and enable them to automate their business processes. The platform caters to the complete value chain of business functions – be it handling F&A, Tax, GST, e-Way Bills, e-Invoicing, Banking, Inventory Management, Order Management, Billing & Invoicing, Cash & Bank Management, Business Intelligence, BP Portal, Procurement & Payroll. (Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same)

Provilac, one of the fastest-growing neo-age premium milk delivery firms in India, announces the launch of lactose-free cow milk. Currently, standing at an annual turnover of 50 Cr., the Angel-funded start-up is planning to massively expand its milk offering. With this launch, Provilac is looking to capture a 10-20 percent market share of the lactose-free milk industry, estimated to be around 350-400 Cr., in the next 2-3 years.

Lactose-free milk is a huge addition to the company’s already existing portfolio of milk and its byproducts. Provilac is already serving 20,000 households in Pune, Mumbai, and Hyderabad. The company, being a completely tech-enabled start-up, is revolutionizing the dairy industry with its state of the art tech platform, its cold supply chain that helps manage the integrity of milk, and the state-of-the-art farms.

Mr. Siddharth Runwal, CEO of Provilac, said, “While there are many players in the business of selling milk, our approach and outlook towards our operations is what truly sets us apart. Milk by nature is highly perishable, thus, keeping it from splitting during the transit, without adding chemical preservatives is a challenge. Maintaining that integrity of milk while transit, without the use of preservatives, is what we have cracked at Provilac. Our focus has always been on innovating and coming up with specialized milks, with all its natural goodness, readily available for the ever-changing customer need. And, the introduction of our lactose-free milk is a testimony to that.“

In recent years, lactose, a form of sugar excessively found in cow milk, intolerance and its implications for the human body have emerged as a noticeable area of concern. According to a national newspaper study in 2020, a staggering 60-65 percent of the Indian populace was found sensitive to lactose-a growing problem that further causes bloating, nausea, vomiting, and abdominal cramps among others.

To promote nutrition and sustenance, Provilac has created a lactose-free variant of cow milk that can be enjoyed by all, especially those with a sensitive digestive system. By adding a catalytic enzyme named ‘lactase’, which breaks down lactose into glucose, the team of experts at Provilac was able to make the cow milk lactose free without jeopardizing the integrity of the product. At a time, when pediatricians have stopped endorsing milk as part of a natural diet, Provilac, by the virtue of its state-of-the-art farm and advanced infrastructure, has heralded a major change in the industry by offering top-quality variants including the likes of A2 milk, homogenized milk, buffalo milk, lactose-free milk, and soon-to-be-launched sugar-free milk.

View article…

(Disclaimer: The above press release comes to you under an arrangement with NewsVoir India and this publication takes no editorial responsibility for the same)

The 16th edition of EORS will be held between 11th and 16th June Biggest-ever collection of 14 lakh styles across 5,000+ brands 1,000 live sessions hosted by ~2,500+ influencers, 750 of which are brand-led on M-Live to showcase their products at EORS offers The platform is geared to handle 16,000 orders per minute and 11 lakh concurrent users during peak 85% of deliveries are expected to be fulfilled by 21,000 Kirana (MENSA) partners, providing them with augmented income opportunities Direct and Indirect Seasonal Employment opportunities are created for 27.5k people to cater to the expected surge in demand during EORS-16 BENGALURU, India, June 10, 2022 /PRNewswire/ — The 16th edition of Myntra’s biannual EORS, India’s grandest fashion event, has arrived, bringing with it the joy and euphoria to the millions of fashion aficionados in the country. The event, which will be held from 11 to 16 June, is going to be bigger than previous versions, comprising the biggest-ever collection of 14 lakh styles across 5,000+ brands. The 6-day event is set to provide unprecedented offers from fashion, lifestyle, beauty and personal care and home categories, catering to over 50 lakh unique customers across the country. Myntra expects over 1 million new customers with over 40% of the overall traffic coming from tier 2 and 3 cities and towns. What should the shoppers be excited about? The brands have specially curated a vast selection with a strong focus on summer essentials, Gen-Z trends, beauty and personal care as well as celebrity-led EORS special collections. First-time shoppers will get INR 500 cashback on their initial transaction, exciting coupons for future use and free delivery for the first 4 orders. On the payments front, there are exciting offers too from banks, such as ICICI Bank and Axis Bank, offering a 10% instant discount, while users of Paytm will get a flat INR 150 cashback on wallet & postpaid transactions. To cater to the changing needs of the customers, Myntra has on-boarded 100 new brands ahead of EORS and increased its style selection by a whopping 40% from the previous July edition, giving shoppers a wide catalogue of products from the best of international and domestic brands, including D2C brands to choose from. Shoppers can opt from an expansive selection of fashion, lifestyle, home decor, beauty and personal care products at sharp prices, from brands like USPA, Puma, HRX, Biba, Roadster, H&M, Mango, Levi’s, Firebolt, ONLY, Nike, Mothercare, Max and Forever21 among others. StyleCast, Myntra’s go-to destination for Gen-Z shoppers has scaled its offerings by 5X since launch to over 35,000 styles, offering the cohort a one-of-a-kind shopping experience during the event. Some of the key category highlights include sportswear, with 2,000+ brands being offered at sharp prices, followed by Beauty and Personal care, bringing ~1,100 brands with over 53k+ styles and special offers. Brands to look out for in this category are, MAC, Maybelline, Lakmé, Bath & Body Works, Anastasia Beverly Hills, and Kama Ayurveda among others. In a first, Myntra is enabling access to hundreds of limited high-value offers on Beauty and Personal Care, including Buy One Get One constructs and an array of unmatched propositions. Other categories to look out for include, men’s casual wear, women’s ethnic, women’s western wear, summer essentials, workwear, accessories, beauty and personal care, kids and sportswear. Myntra is providing a unique shopping experience through its M-Live property, to those shoppers who get inspired by influencers’ choices and absorb their content to create styles for themselves. Myntra’s social commerce propositions, Myntra Studio and M-Live will host ~1,000 sessions by ~1,000 influencers with shoppable content. ~75% of these sessions will be brand-led, wherein brands will present their selection through the creators’ content at EORS offers. Over 30 brand-led sessions will be hosted on M-Live, creating a never-before opportunity for brands to connect with their consumer base. Speaking about EORS, Nandita Sinha, CEO, Myntra, said, “Over the years, EORS has become one of the most sought-after fashion events in the country. The 16th edition, like all the successive ones, will be bigger on every front, be it brands, selections or styles, making for a joyous 6-day carnival for all the fashion and beauty aficionados out there. The event is also an opportunity for Myntra to give a boost to the fashion ecosystem, from Kirana store partners, Taavi artisans, small and medium scale brands and sellers to the supply chain partners. Our constant effort is to take the fashion quotient of the consumers high while also helping weave the future of our ecosystem partners.” About Myntra  Myntra is one of India’s leading platforms for fashion brands and in m-commerce play. An integral part of the Flipkart Group, Myntra brings together technology and fashion to create the best experience in the fashion and lifestyle space in India. Myntra platform offers access to a wide range of over 5,000+ leading fashion and lifestyle brands in the country such as H&M, Levis, U.S. Polo Assn., Tommy Hilfiger, Louis Philippe, Jack & Jones, MANGO, Forever 21, Urbanic, Marks & Spencer, W, Biba, Nike, Puma, Crocs, M.A.C, and Fossil and many more. Myntra services over 19,000 pin codes across the country. Photo: https://mma.prnewswire.com/media/1837157/EORS_is_Here.jpg (Disclaimer: The above press release comes to you under an arrangement with PRNewswire India and this publication takes no editorial responsibility for the same)